Eculizumab

Red

Brand Name(s):Soliris

Indication:Delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Paroxysmal nocturnal haemoglobinuria and Atypical hemolytic uremic syndrome (Ahus) Myasthenia gravis (refractory generalized) Neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease

Rationale:1,2,8

Considered:Nov-11

Review Date:Nov-25

Comments:
Eculizumab is recommended to be available as a treatment option through routine commissioning for delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies.

The SPC has been updated with a new indication – neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody-positive with a relapsing course of the disease. ………………………… NHS England will commission emicizumab as prophylaxis in adults and children with severe congenital haemophilia A (defined as factor VIII level <1 IU/dL, or <1% of normal) without current inhibitors to prevent bleeding episodes.………..............................NICE HST1 Eculizumab for treating Atypical hemolytic uremic syndrome (aHUS). Information at:http://www.nice.org.uk/guidance/hst1/resources/eculizumab-for-treating-atypical-haemolytic-uraemic-syndrome-1394895848389 Jan 2015